ACC: Shingles Vaccine May Lower Risk for MACE in Patients With Atherosclerotic CVD

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on March 19, 2026.

via HealthDay

THURSDAY, March 19, 2026 -- For adults aged 50 years and older with a diagnosis of atherosclerotic cardiovascular disease (ASCVD), herpes zoster (HZ) vaccination is associated with a lower risk for major adverse cardiovascular events (MACE) and secondary cardiovascular outcomes, according to a study scheduled for presentation at the annual meeting of the American College of Cardiology, being held from March 28 to 30 in New Orleans.

Robert Nguyen, M.D., and Aditya Desai, M.D., from the University of California in Riverside, conducted a retrospective cohort study using data from the U.S. TriNetX database in adults aged 50 years and older with a diagnosis of ASCVD between Jan. 1, 2018, and Jan. 1, 2024, to examine whether HZ vaccination reduces cardiovascular risk in this population. After propensity score matching, 275,304 HZ-vaccinated and 275,304 unvaccinated patients were included.

The researchers found that HZ vaccination was associated with significantly lower risks for MACE, all-cause mortality, incident myocardial infarction, and stroke (hazard ratios, 0.54, 0.39, 0.73, and 0.73, respectively). In addition, HZ vaccination was associated with reduced risks for incident venous thromboembolism, heart failure, and atrial fibrillation or flutter (hazard ratios, 0.63, 0.67, and 0.70, respectively).

"This vaccine has been found over and over again to have cardioprotective effects for reducing heart attack, stroke and death," Nguyen said in a statement. "Looking at the highest risk population, those with existing cardiovascular disease, these protective effects might be even greater than among the general public."

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-03-20 01:53

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

ACC: Shingles Vaccine May Lower Risk for MACE in Patients With Atherosclerotic CVD

Read more

Disclaimer

Popular Keywords